Avalon Globocare Corp. · NASDAQ:ALBT
Avalon Globocare — Investor Presentation (October 2020)
37 slides from Avalon Globocare's investor presentation, October 2020
Slide 1: Corporate Presentation
Corporate Presentation October 2020 www.avalon-globocare.com NASDAQ: AVCO
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements contained in this presentation may constitute “forward-looking statements”, which provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual
Slide 3: Corporate Overview
Corporate Overview Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage leading bio-developer of innovative and transformative cell-based technology and therapeutics • History: Founded in 2016; Headquarters in Freehold, NJ; ~ 30 FTE (including subsidiaries) • Core Technology Platforms; R&D Prog
Slide 4: Investment Highlights
Investment Highlights • Successfully uplisted from OTCQB to NASDAQ in December 2018 • Purchased headquarters building in Freehold/New Jersey in 2016 (USD $8M), which generates average annual revenue of USD $1.2M • Successfully filed for USD $50M mixed shelf offering (S3) in January 2019; subsequentl
Slide 5: Operating Laboratories
Operating Laboratories • Joint laboratory at Weill • Beijing Lu Daopei Hospital, • Nanjing BenQ Hospital, China Cornell Medicine, USA China • Nanjing Epicon Biotech: JV • Co-development program between Avalon GloboCare with cGMP Cell Engineering • Exosome preparation QC/QA & Nanjing Unicorn Facility
Slide 6: Major Clinical Bases and Joint Laboratories
Major Clinical Bases and Joint Laboratories • Beijing Lu Daopei Hospital • Hebei Yanda Lu Daopei Hospital • Shanghai Lu Daopei Hospital • Lu Daopei Medical Group • Wuhan Biolake Stem Cell Bank • Lu Daopei Hematology Research Institute • Performed 1081 cases of HSCT in 2019 • Performed over 1000 case
Slide 7: Operating Model: Seamless Vertical Integration
Operating Model: Seamless Vertical Integration Upstream: Innovation, R&D, IPs • QTY-code engineered novel targets; AVA-TrapTM • Next-Gen multi-target, RNA-based Flash-CARTM Upstream • Angiogenic Exosomes; ACTEXTM • S-layer COVID-19 vaccine development Better and Safer Therapeutic Options Midstream:
Slide 8: Senior Management / BOD / SCAB
Senior Management / BOD / SCAB Board of Directors Senior Management 8 8
Slide 9: Core Technology Platform 1: Immune Effector Cell Therapy
Core Technology Platform 1: Immune Effector Cell Therapy 9
Slide 10: Global Immuno-oncology Therapy Market
Global Immuno-oncology Therapy Market 10
Slide 11: Immune Effector Cell Therapy Pipeline Candidates
Core Technology Platform: Immune Effector Cell Therapy Avalon’s Cellular Medicine Pipeline Candidates: Targeting Broad Bandwidth of Immuno-Oncology QTY Protein/Ab Design Cytokine / Chemokine Decoy Receptors “AVA-TrapTM” Multiplex Expansion Activators CAR* Macrophage Dendritic Cell AVA-001 4-1BB CAR-
Slide 12: AVA-001 (Third-Gen CAR-T)
AVA-001 (Third-Gen CAR-T) 12
Slide 13: AVA-001 (Third-Gen CAR-T)
AVA-001 (Third-Gen CAR-T) 13
Slide 14: AVA-001 (Third-Gen CAR-T)
AVA-001 (Third-Gen CAR-T) • Complete Remission (CR) Rate: 90% • Minimal and well tolerated adverse side effects: no neurotoxiciy or > Grade 1 cytokine release syndrome observed • All patients achieved CR successfully proceeded to allogeneic BMT with curative intent • This paradigm of bridging CAR T-
Slide 15: AVA-101 (Transposon CAR-T)
AVA-101 (Transposon CAR-T) Avalon’s next-generation transposon-based CAR-T technology: • Multiple targets (increased efficacy) • Applicable in multiple cell types: CAR-T, CAR-NK, universal CAR-T/-NK • Transposon-engineered, non-viral vector (expanded package) • “Safety-switch” control mechanism; red
Slide 16: Flash-CAR -- A Multiplex, RNA-CAR Platform
FLASH-CARTM -- A Multiplex, RNA-CAR Platform 16
Slide 17: Flash-CAR -- A Multiplex, RNA-CAR Platform
FLASH-CARTM -- A Multiplex, RNA-CAR Platform Multiplex, RNA-CAR Covers Broad Spectrum of Immuno-Oncology Targets • Auto- or Allo-CAR T targeting multiple tumor antigens Simultaneous Activation of • Proliferation inducer for in vivo expansion of CAR-T Tumor-Attacking Immune Cells: • Safety target/swi
Slide 18: Avalon's Clinical Study Pipeline: Immune Effector Cell Therapy Candidates
Avalon’s Clinical Study Pipeline: Immune Effector Cell Therapy Candidates Design control / Clinical Development Program Pre-clinical IND enabling Regulatory Pathway Safety Efficacy Pivotal AVA-001 Initiated in Completed in R/R B-ALL China FDA (4-1BB CAR-T) 2019 Q3 2020 Q2 AVA-101 Initiated in Initia
Slide 19: Avalon Combat COVID-19 Taskforce (ACCT)
Avalon Combat COVID-19 Taskforce (“ACCT”) The sickness and ripple effect of the COVID-19 global pandemic has been severely affecting all walks of life, imposing tremendous medical, social and financial burdens to our society. Avalon has launched Avalon Combat COVID-19 Taskforce (“ACCT”), aiming to e
Slide 20: Avalon Combat COVID-19 Taskforce (ACCT)
Avalon Combat COVID-19 Taskforce (“ACCT”) Diagnostics Therapeutics Vaccines • SARS-CoV-2 antibody-based • QTY code technology • S-layer nanotechnology IgG/IgM rapid tests • Cytokine/chemokine decoy • Novel COVID-19 vaccines • SARS-CoV-2 nucleic acid-based receptor proteins delivered as intranasal/ o
Slide 21: Avalon-MIT QTY Code Co-development Program: AVA-Trap
Avalon-MIT QTY Code Co-development Program: AVA-TrapTM QTY code-generated novel therapeutic targets for cancer immunotherapy and other clinical applications Designed QTY proteins directly serve as QTY Proteins as Decoy Receptors recombinant monoclonal antibodies Design of the QTY receptors resemble
Slide 22: Avalon-MIT QTY Code Co-development Program: AVA-Trap
Avalon-MIT QTY Code Co-development Program: AVA-TrapTM 22
Slide 23: Avalon-MIT QTY Code Co-development Program: AVA-Trap
Avalon-MIT QTY Code Co-development Program: AVA-TrapTM Future Workplan: • Q4 2020 – Q2 2021: Bioproduction of GMP-grade AVA-TrapTM proteins; in vivo testing in humanized mouse model of cytokine storm; toxicology testing; design of hemo-purification/hemo- dialysis device prototype • Q3 2021: Initiati
Slide 24: Avalon-BOKU Co-development Program: S-Layer COVID-19 Candidate Vaccine
Avalon-BOKU Co-development Program: S-Layer COVID-19 Candidate Vaccine Uwe B. Sleytr, Ph.D. Professor Emeritus, BOKU Full Member of The Austrian Academy of Sciences Scientific Advisor, Avalon GloboCare S-Layer Conjugate Protein as Candidate COVID-19 Vaccine via Intra-Nasal/Oral Routes 24
Slide 25: Avalon-BOKU Co-development Program: S-Layer Based COVID-19 Mucosal Vaccine
Avalon-BOKU Co-development Program: S-Layer Based COVID-19 Mucosal Vaccine Self-assembling peptide unit of S-layer Conjugated Antigens (such as COVID-19 Spike Protein) or molecules for targeted delivery Inner core nanocarriers: Liposomes / Emulsomes loaded with DNAs, RNAs, therapeutic agents ..etc 2
Slide 26: Avalon-BOKU Co-development Program: S-Layer Based COVID-19 Mucosal Vaccine
Avalon-BOKU Co-development Program: S-Layer Based COVID-19 Mucosal Vaccine S-Layer fusion protein as intranasal/oral vaccine against COVID-19 and other airborne viruses: (1) Eliciting DTH and immune-protective antibody responses without the use of extraneous adjuvants (2) Can be administered by seve
Slide 27: Allogeneic Mesenchymal Stromal Cells (MSCs)
Allogeneic Mesenchymal Stromal Cells (MSCs) Allogeneic MSC Therapy for: - Acute Respiratory Distress Syndrome (ARDS) - Acute Graft-Versus-Host Disease (aGVHD) - Multi-System Inflammatory Syndrome (MIS) - Cytokine Storm (ACTEX-M) 27
Slide 28: Core Technology Platform: Stem Cell Exosome Technology
Core Technology Platform: Stem Cell Exosome Technology Exosomal biomarkers as disease-associated “Liquid Biopsy” Diagnostics Clinical-grade, stem cell-derived exosomes as Regenerative Therapeutics 28
Slide 29: Global Market for Stem Cell Exosomes
Global Market for Stem Cell Exosomes 29
Slide 30: Avalon's Clinical-Grade ACTEX
Avalon’s Clinical-Grade ACTEXTM Accreditation/Standardization Infrastructures Clinical-Grade ACTEXTM Stem/Progenitor Cells (Avalon Clinical-Grade Bio-production Tissue-Specific Exosomes) Standardization Strategic Partnership ACTEXTM-based Products • Weill Cornell Medicine Strategic Partnership June
Slide 31: Avalon's Clinical-Grade ACTEX
Avalon’s Clinical-Grade ACTEXTM Types ACTEX Cell-of-Origin Applications AVA-202 AVA-203 31
Slide 32: Integrated Strategy for ACTEX-based Product Development and Commercialization
Integrated Strategy for ACTEX-based Product Development and Commercialization Engineered Exosomes “Biofactory” Strategic Partnership Enhanced Formulations & Efficacy Commercialization HydroPeptide Bioinformatics “Exosomics” Personalized Medicine 32
Slide 33: Partnership with HydroPeptide
Partnership with HydroPeptide • Network of over 50 prominent dermatology practice groups • “Power Serum” hydropeptide formulation with well established marketing channels worldwide • Signed strategic partnership agreement and MTA; reformulation of clinical-grade ACTEX-HP combination to be initiated
Slide 34: Bioprocessing / Bioproduction / CDMO
Bioprocessing / Bioproduction / CDMO 34
Slide 35: Bioprocessing / Bioproduction / CDMO
Bioprocessing / Bioproduction / CDMO Standardized Automation Process Development Bio-production and Training for Cellular Medicines 35
Slide 36: Corporate Council, American Society of Transplantation and Cellular Therapy (ASTCT)
Corporate Council, American Society of Transplantation and Cellular Therapy (ASTCT) Avalon GloboCare, part of 25 elite members of ASTCT’s Corporate Council, dedicated to accelerate global development of cellular medicines Source: www.asbmt.org 36
Slide 37: Avalon GloboCare Corp. Contact
GLOBOCARE CORP. al 3X AVALON (NASDAQ; AVCO) Contact: David Jin, M.D., Ph.D. President & CEO [email protected] Luisa Ingargiola CFO [email protected]
Avalon GloboCare — Investor Presentation (October 2020) on 6ix